Cerebrolysin is a peptide based Nootropic with an impressive 165 human studies referenceable on Pubmed, over 30 human clinical trials have been done with Cerebrolysin in the past 10 years alone which is an appreciable amount of research. Piracetam has approximately the same amount of recent human trials. It is now hard to believe, but Cerebrolysin – perhaps the most efficient peptide nootropic – was developed when the scientific community had a very limited understanding of how the central nervous system works.
Gerhart Harrer, an Austrian Professor, created Cerebrolysin in 1949. Today, this nootropic peptide used as a treatment for various cerebral disorders in 44 countries. This supplement is included in the Russian List of Vital & Essential Drugs.
On label indications:
- Strokes and stroke complications
- Alzheimer’s disease and other types of dementia
- Traumatic brain injuries
- Spinal cord injuries
- ADHD in children
- Antidepressant-resistant depression
- Other cerebral diseases
Mechanism of Action: Cerebrolysin promotes
- Brain-derived neurotrophic factor
- Glial cell line derived neurotrophic factor
- Nerve growth factor
- Nerve growth factor GF-1
It does cross the blood brain barrier.
Country of Manufacture: Austria
IT CAN BE KEPT OUTSIDE OF REFRIGERATOR WITH TEMPERATURE BELOW 25 ℃ (77.00 ℉)
Here is the original 84-pages Cerebrolysin Monograph from EverNeuro Pharma, where you can find a lot of information